Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

This phase 3 SUNMO trial evaluated the combination of mosunetuzumab and polatuzumab vedotin (Mosun-Pola) versus rituxima...

Continue ReadingMosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

Metagenomic next-generation sequencing for concurrent diagnosis of infections and malignancies in patients with lung lesions: a single-center prospective study.

This study evaluates the dual diagnostic utility of metagenomic next-generation sequencing (mNGS) in distinguishing pulm...

Continue ReadingMetagenomic next-generation sequencing for concurrent diagnosis of infections and malignancies in patients with lung lesions: a single-center prospective study.